File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

TitleInterim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Authors
Ma, XLLalezari, JNguyuen, TBae, HoSchiff, ERFung, SYuen, RMFHassanein, THann, HWElkhashab, MDieterich, DSulkowski, MKwo, PNahass, RAgarwal, KRamji, APark, JRavendhran, NChan, SWeilert, FHan, SHAyoub, WGane, EJacobson, IBennett, MHuang, QYan, RHuey, VRuby, ELiaw, SColonno, RLopatin, U
Issue Date2019
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress 2019, Vienna, Austria, 10-14 April 2019. Abstracts Book in Journal of Hepatology, 2019, v. 70 n. 1, Suppl., p. e130 How to Cite?
DOI: http://dx.doi.org/10.1016/S0618-8278(19)30230-0
DescriptionPoster Presentation - no. LBO-06
Persistent Identifierhttp://hdl.handle.net/10722/275330
ISSN
0168-8278
2021 Impact Factor: 30.083
2020 SCImago Journal Rankings: 7.112
ISI Accession Number ID
WOS:000463481700231

 

DC FieldValueLanguage
dc.contributor.authorMa, XL-
dc.contributor.authorLalezari, J-
dc.contributor.authorNguyuen, T-
dc.contributor.authorBae, Ho-
dc.contributor.authorSchiff, ER-
dc.contributor.authorFung, S-
dc.contributor.authorYuen, RMF-
dc.contributor.authorHassanein, T-
dc.contributor.authorHann, HW-
dc.contributor.authorElkhashab, M-
dc.contributor.authorDieterich, D-
dc.contributor.authorSulkowski, M-
dc.contributor.authorKwo, P-
dc.contributor.authorNahass, R-
dc.contributor.authorAgarwal, K-
dc.contributor.authorRamji, A-
dc.contributor.authorPark, J-
dc.contributor.authorRavendhran, N-
dc.contributor.authorChan, S-
dc.contributor.authorWeilert, F-
dc.contributor.authorHan, SH-
dc.contributor.authorAyoub, W-
dc.contributor.authorGane, E-
dc.contributor.authorJacobson, I-
dc.contributor.authorBennett, M-
dc.contributor.authorHuang, Q-
dc.contributor.authorYan, R-
dc.contributor.authorHuey, V-
dc.contributor.authorRuby, E-
dc.contributor.authorLiaw, S-
dc.contributor.authorColonno, R-
dc.contributor.authorLopatin, U-
dc.date.accessioned2019-09-10T02:40:23Z-
dc.date.available2019-09-10T02:40:23Z-
dc.date.issued2019-
dc.identifier.citationThe International Liver Congress 2019, Vienna, Austria, 10-14 April 2019. Abstracts Book in Journal of Hepatology, 2019, v. 70 n. 1, Suppl., p. e130-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/275330-
dc.descriptionPoster Presentation - no. LBO-06-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.relation.ispartofInternational Liver Congress 2019-
dc.titleInterim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0618-8278(19)30230-0-
dc.identifier.hkuros304582-
dc.identifier.hkuros307201-
dc.identifier.volume70-
dc.identifier.issue1, Suppl.-
dc.identifier.spagee130-
dc.identifier.epagee130-
dc.identifier.isiWOS:000463481700231-
dc.publisher.placeNetherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats